Further investigations are required to determine whether CPT and its analogues are able to modulate the NF-κB/Lin28/Let-7 pathway, as new miRNA-based therapies could be developed in the context of viral arthritis, but also other inflammatory diseases, such as autoimmune diseases, type 2 diabetes and obesity. This evidence concerns the gene LIN28A and autoimmune disease.